1. Scrip
  2. >>R&D

Bayer’s Nubeqa Study Success Will Broaden Its Prostate Cancer Reach

 
• By Andrew McConaghie

The Phase III study success is good news, but not the surprise upside that Bayer needs to lift investor sentiment.

Bayer US
• Source: Shutterstock

Nubeqa is one of just a few new drugs that Bayer can count on for growth, and the androgen receptor inhibitor has just delivered again with a Phase III success in prostate cancer.

Nubeqa (darolutamide) has notched up a win in the ARANOTE study, proving its value in another subset of patients, this time men with metastatic hormone-sensitive prostate cancer (mHSPC).

Key Takeaways

  • Nubeqa is on course to earn $1bn this year, and is one of Bayer’s few bright spots.

  • The results set it up...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

More from R&D

Sanofi Plays It Safer With Blueprint Buy After Bumpy 2025

 
• By Kevin Grogan

But the French major is still keen on early-stage M&A.

Pipeline Watch: Eight Approvals And Nine Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

BREAKING NEWS: Sanofi Bets $9.5bn To Bag Blueprint

 
• By Kevin Grogan

Buy boosts the French major's immunology pipeline.